Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer.
|Abstract||The favorable prognosis of women with non-small-cell lung cancer (NSCLC) compared to men might be explained by sex hormone-related mechanisms. We investigated whether this observation could be explained by the expression of estrogen receptor-alpha (ER-α) in tumor tissue.|
Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.
|Journal Title||anticancer research|
|Publication Year Start||2018-01-01|
PMID- 29599348 OWN - NLM STAT- MEDLINE DCOM- 20180412 LR - 20180412 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 38 IP - 4 DP - 2018 Apr TI - Expression of Estrogen Receptor-alpha and Survival in Advanced-stage Non-small Cell Lung Cancer. PG - 2261-2269 AB - BACKGROUND/AIM: The favorable prognosis of women with non-small-cell lung cancer (NSCLC) compared to men might be explained by sex hormone-related mechanisms. We investigated whether this observation could be explained by the expression of estrogen receptor-alpha (ER-alpha) in tumor tissue. MATERIALS AND METHODS: Archived, formalin fixed, paraffin embedded tumor tissue samples were retrospectively analyzed for nuclear expression of ER-alpha with immunohistochemistry. RESULTS: Biopsies from 222 patients were analyzed. Twenty-three percent were ER-alpha positive. Fifty-four percent of the patients were men and 46% of the tumors were adenocarcinomas. One hundred-nine (49%) patients received pemetrexed and carboplatin and 113 (51%) received gemcitabine and carboplatin. Females with ER-alpha positive tumors who received PC had a substantial survival benefit over all other groups (20 vs. 4.6 months; p=0.003). CONCLUSION: ER-alpha is an independent prognostic factor in advanced NSCLC and might also be a predictive factor for response to pemetrexed/carboplatin in women. CI - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Lund-Iversen, Marius AU - Lund-Iversen M AD - Department of Pathology, Oslo University Hospital, Oslo, Norway [email protected] AD - Institute of Clinical Medicine, University of Oslo, Oslo, Norway. FAU - Scott, Helge AU - Scott H AD - Department of Pathology, Oslo University Hospital, Oslo, Norway. AD - Institute of Clinical Medicine, University of Oslo, Oslo, Norway. FAU - Strom, Erik H AU - Strom EH AD - Department of Pathology, Oslo University Hospital, Oslo, Norway. FAU - Theiss, Noah AU - Theiss N AD - Ventana Medical Systems, Tucson, AZ, U.S.A. FAU - Brustugun, Odd Terje AU - Brustugun OT AD - Section of Oncology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway. FAU - Gronberg, Bjorn H AU - Gronberg BH AD - Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway. AD - The Cancer Clinic, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway. LA - eng PT - Clinical Trial, Phase III PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - 0 (Estrogen Receptor alpha) RN - 0 (estrogen receptor alpha, human) RN - 04Q9AIZ7NO (Pemetrexed) RN - 0W860991D6 (Deoxycytidine) RN - B76N6SBZ8R (gemcitabine) RN - BG3F62OND5 (Carboplatin) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Carboplatin/administration & dosage MH - Carcinoma, Non-Small-Cell Lung/drug therapy/*metabolism/mortality/pathology MH - Deoxycytidine/administration & dosage/analogs & derivatives MH - Disease Progression MH - Estrogen Receptor alpha/*metabolism MH - Female MH - Humans MH - Immunohistochemistry MH - Lung Neoplasms/drug therapy/*metabolism/mortality/pathology MH - Male MH - Middle Aged MH - Pemetrexed/administration & dosage MH - Retrospective Studies OTO - NOTNLM OT - *Prognostic factor OT - *estrogen receptor OT - *first-line chemotherapy OT - *gender difference OT - *immunohistochemistry OT - *palliative chemotherapy OT - *sex hormones EDAT- 2018/03/31 06:00 MHDA- 2018/04/13 06:00 CRDT- 2018/03/31 06:00 PHST- 2018/02/13 00:00 [received] PHST- 2018/03/02 00:00 [revised] PHST- 2018/03/05 00:00 [accepted] PHST- 2018/03/31 06:00 [entrez] PHST- 2018/03/31 06:00 [pubmed] PHST- 2018/04/13 06:00 [medline] AID - 38/4/2261 [pii] AID - 10.21873/anticanres.12470 [doi] PST - ppublish SO - Anticancer Res. 2018 Apr;38(4):2261-2269. doi: 10.21873/anticanres.12470.